HAEGARDA Drug Profile

Summary for Tradename: HAEGARDA

High Confidence Patents:	5
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HAEGARDA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HAEGARDA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,105,423	2037-12-11	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,226,595	2035-06-16	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,478,690	2035-11-25	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	10,874,788	2036-07-25	DrugPatentWatch analysis and company disclosures
Csl Behring Gmbh	HAEGARDA	c1 esterase inhibitor subcutaneous (human)	For Injection	125606	9,616,111	2035-09-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HAEGARDA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for HAEGARDA

Country	Patent Number	Estimated Expiration
Japan	2019073546
Hong Kong	1250912
World Intellectual Property Organization (WIPO)	2017019640
Japan	2018119002
Montenegro	02865
Israel	241549

Market Dynamics and Financial Trajectory for HAEGARDA

Last updated: April 14, 2026

What is the current market landscape for HAEGARDA?

HAEGARDA (C1 Esterase Inhibitor [Human]) is marketed by Takeda Pharmaceutical Company. Since its approval in 2018 by the U.S. Food and Drug Administration (FDA), it has positioned itself within the hereditary angioedema (HAE) treatment segment. The HAE market is expected to grow due to increased diagnosis rates and expanding patient populations across regions.

Market Size and Growth:
As of 2023, the global HAE treatment market was valued at approximately USD 950 million. It is projected to reach USD 1.7 billion by 2030, with a compound annual growth rate (CAGR) of 8.3% (Fortune Business Insights, 2023).

Key Competitors:

• Ruconest (Veyx-Cell): Powdered form, recombinant C1 Esterase Inhibitor.
• Berinert: Plasma-derived C1 Esterase Inhibitor, marketed by CSL Behring.
• Takhzyro (Lanadelumab): Monoclonal antibody marketed by Takeda, approved in 2018.
• Firazyr (Icatibant): Used for acute attacks, marketed by Shire (now part of Takeda).

How does HAEGARDA's market performance compare to competitors?

Product	Approved Year	Administration	Indications	Price (per dose)	Market Share (2023)
HAEGARDA	2018	IV	Prophylaxis for HAE attacks	USD 6,000	35%
Takhzyro	2018	SC	Prophylaxis for HAE attacks	USD 3,500	30%
Ruconest	2008	IV	Acute attacks, prophylaxis	USD 12,000	10%
Berinert	2009	IV	Acute attacks	USD 7,000	15%
Firazyr	2009	SC	Acute attacks	USD 1,500	10%

Market share trends:
HAEGARDA has maintained a leading position in prophylactic treatments. Its intravenous (IV) administration results in higher healthcare provider involvement, which impacts patient preference and adherence.

What factors influence HAEGARDA’s market trajectory?

Regulatory landscape

• US approval was granted in 2018.
• European approval followed in 2019.
• Ongoing regulatory reviews in Asia-Pacific markets, with launches anticipated within 1-2 years.

Pricing and reimbursement

• Pricing remains a critical factor; HAEGARDA's USD 6,000 per dose influences payer negotiations.
• Managed care plans favor orally administered or subcutaneously injected therapies like Takhzyro due to convenience.
• Reimbursement policies vary by region; constraints in certain markets limit access.

Patient adherence and convenience

• IV administration poses challenges for outpatient management.
• The development of subcutaneous options like Takhzyro impacts market share.

Clinical differentiation

• HAEGARDA’s specific indication as a prophylactic agent for HAE attack prevention.
• Real-world data demonstrate efficacy and safety, supporting its use as a first-line prophylactic agent.

How does HAEGARDA's financial outlook look?

Revenue projections

• 2022 sales: USD 300 million (Takeda annual report, 2022).
• Estimated 2023 sales: USD 350 million, driven by increased adoption.
• Market growth driven by new diagnoses and expanded insurance coverage.

Revenue drivers

• Geographic expansion into Asia and Latin America.
• Extension of indications for prophylaxis in pediatric patients pending regulatory approval.
• Potential for label expansion to include additional prophylaxis indications.

Cost considerations

• Manufacturing costs for plasma-derived products fluctuate, impacting margins.
• Increased R&D investment in delivery innovations and biosimilars.

Risks

• Competition from biosimilars could erode market share by 2025.
• Pricing pressures due to healthcare cost containment policies.
• Regulatory hurdles in emerging markets.

What is the outlook for the future?

• Market penetration will grow with new product launches, especially subcutaneous formulations.
• Takeda's strategic focus on expanding global access and reducing administration burden will influence adoption rates.
• Revenue growth is forecasted to reach USD 600 million by 2025, assuming continued market share gains and international expansion.

Key Takeaways

• HAEGARDA has a dominant position in prophylactic HAE treatment but faces competition from newer, more convenient therapies.
• The overall market is expanding with increased diagnosis and regional expansion.
• Pricing and administration route influence market share gains.
• Biosimilar entry and healthcare policy changes pose significant risks.
• Revenue is expected to grow steadily, driven by expanded access and potential indication extensions.

FAQs

Q1: What are the main competitive advantages of HAEGARDA?
A1: Its proven efficacy and safety profile for long-term prophylaxis position HAEGARDA as a preferred option where intravenous administration is acceptable, especially in healthcare settings with infusion capabilities.

Q2: How might biosimilar products impact HAEGARDA’s revenue?
A2: Biosimilars entering the plasma-derived C1 esterase inhibitors market could decrease HAEGARDA’s market share, particularly in regions with aggressive price negotiations and cost-sensitive healthcare systems.

Q3: What are the development opportunities for HAEGARDA?
A3: Routes to growth include regulatory approval for pediatric use, alternative formulations such as subcutaneous delivery, and broader indication extensions for prophylactic use.

Q4: How does pricing influence market dynamics?
A4: High per-dose costs limit affordability and access, especially in regions with strict reimbursement policies. Competitive pricing and value-based pricing strategies will be critical for market expansion.

Q5: What is the significance of regional regulatory approvals?
A5: Growing approvals in Asia-Pacific, Latin America, and other emerging markets will diversify revenue streams and offset saturation in North America and Europe.

---

References:
[1] Fortune Business Insights. (2023). Hereditary Angioedema Treatment Market Size, Share & Industry Analysis.
[2] Takeda Pharmaceutical Company. (2022). Annual Report.
[3] FDA. (2018). Approved Drug Products: HAEGARDA.